SUTRO BIOPHARMA, INC. Effective Income Tax Rate Reconciliation Fdii Percent
SUTRO BIOPHARMA, INC. (STRO) reported Effective Income Tax Rate Reconciliation Fdii Percent of -1.40% for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent · last filed 2025-03-13
- SUTRO BIOPHARMA, INC. effective income tax rate reconciliation fdii percent for fiscal 2023 was -1.40%.
| Period end | Effective Income Tax Rate Reconciliation Fdii Percent 12 month | Effective Income Tax Rate Reconciliation Fdii Percent 12 month as first filed |
|---|---|---|
| 2023-12-31 | -1.40% 10-K · filed 2025-03-13 | 1.50% 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |